The impact of time-to-balloon on outcomes in patients undergoing modern primary angioplasty for acute myocardial infarction

Singapore Medical Journal

Volumn 48, Issue 2, 2007, Pages 131-136

  Soon, Chao Yang ^a   Chan, W X ^b   Tan, H C ^b  

^a ALEXANDRA HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Angioplasty; Balloon angioplasty; Ischaemic heart disease; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DOOR TO BALLOON TIME; EARLY INTERVENTION; FEMALE; HEALTH CARE ACCESS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARAMETER; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM TO BALLOON TIME; TREATMENT OUTCOME; EPIDEMIOLOGY; HEART INFARCTION; METHODOLOGY; MIDDLE AGED; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTORS;

EID: 34447525296     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-5.
2. Comment in: ACP J Club 1996; 126:31.
3. Lancet 1996; 348:1312-3.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-22. Erratum in: Lancet 1994; 343:742.
5. Comment in: Lancet 1994; 343:912.
6. Lancet 1994; 343:912-3.
7. Lancet 1994; 343:1225-6.
8. Lancet 2001; 357:1367-8.
9. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996; 27:1646-55.
10. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941-7.
11. Comment in: JAMA 2000; 283:2988-9.
12. JAMA 2001; 285:1701; author reply 1701-2.
13. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32:1312-9.
14. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109:1223-5.
15. Comment in: Circulation 2004;109:1806-8.
16. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. I: Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56:786-94.
17. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h), and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23:550-7.
18. Comment in: Eur Heart J 2002; 23:1146-8.
19. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-82.
20. Comment in: ACP J Club 1994; 120 suppl 2:33.
21. N Engl J Med 1993; 329:723-5.
22. N Engl J Med 1994; 330:504; author reply 505-6.
23. N Engl J Med 1994;330:505; author reply 505-6.
24. N Engl J Med 1994; 331:277-8.
25. N Engl J Med 1998; 338:545-6; author reply 546-7.
26. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-22. Erratum in: N Engl J Med 1994; 330:516.
27. Comment in: N Engl J Med 1993; 329:1650-2.
28. N Engl J Med 1994; 330:1089; author reply 1089-90.
29. Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739-46.
30. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-66.
31. Comment in: N Engl J Med 2002; 347:367-8; author reply 367-8.
32. N Engl J Med 2002; 346:954-5.
33. Gibson CM, de Lemos JA, Antman EM; TIMI Study Group. Time is muscle in primary PCI: the strength of the evidence grows. Eur Heart J 2004; 25:1001-2.
34. Comment on: Eur Heart J 2004; 25:1009-13.
35. De Luca G, van't Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004; 25:1009-13.
36. Comment on: Eur Heart J 2004; 25:1001-2.
37. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2004; 44:671-719. Erratum in: J Am Coll Cardiol 2005; 45:1376.
38. Comment in: J Am Coll Cardiol 2005; 45:1551.
39. J Am Coll Cardiol 2005; 45:1552; author reply 1552-3.
40. Antman EM, Van de Werf F. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation 2004; 109:2480-6.
41. Dauerman HL, Sobel BE. Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol 2003; 42:646-51.